Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen.

Trial Details

NCT ID
NCT04570943
Phase
PHASE2
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Gabrinox
  • MRI-GUIDED STEREOTACTIC RADIOTHERAPY
Locations (sample)
  • Marseille, Bouches-du-Rhône, France|43.29695,5.38107
  • Nîmes, Gard, France|43.83665,4.35788
  • Montpellier, Herault, France|43.61093,3.87635
  • Montpellier, Hérault, France|43.61093,3.87635
  • Clichy, France|48.90018,2.30952

Key Eligibility Criteria

  • Patient aged from 18 to 75 years at the date of signature of the consent form
  • Histologically or cytologically proven pancreatic adenocarcinoma
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Non-resectable tumour according to the National Comprehensive Cancer Network (NCCN) 1.2015 recommendations after external review of imaging data by…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →